Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study
Purpose This article was to collect data on the safety of coronavirus disease 2019 (COVID-19) vaccines in children with underlying medical conditions. Methods We constructed a prospective cohort of children and adolescents aged 5 to 19 years who had received at least one dose of COVID-19 vaccine. Pa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society of Pediatric Nephrology
2023-06-01
|
| Series: | Childhood Kidney Diseases |
| Subjects: | |
| Online Access: | http://chikd.org/upload/pdf/ckd-23-004.pdf |
| _version_ | 1797692790081060864 |
|---|---|
| author | Naye Choi Seung-Ah Choe Yo Han Ahn Young June Choe Ju-Young Shin Nam-Kyong Choi Seong Heon Kim Hee Gyung Kang |
| author_facet | Naye Choi Seung-Ah Choe Yo Han Ahn Young June Choe Ju-Young Shin Nam-Kyong Choi Seong Heon Kim Hee Gyung Kang |
| author_sort | Naye Choi |
| collection | DOAJ |
| description | Purpose This article was to collect data on the safety of coronavirus disease 2019 (COVID-19) vaccines in children with underlying medical conditions. Methods We constructed a prospective cohort of children and adolescents aged 5 to 19 years who had received at least one dose of COVID-19 vaccine. Patients diagnosed with and treated for chronic kidney disease, autoimmune disease, or other chronic conditions at the Seoul National University Children’s Hospital were recruited from June to December 2022. A mobile survey questionnaire was sent to their guardians. The presence of adverse events on the day (day 0), 3 weeks (day 21), and 6 months (day 180) after the 1st dose of COVID-19 vaccine was recorded by the guardians. Results A total of 73 children participated. The median age was 14 years, and 64.4% of the patients were male. On the day of immunization, 65.8% of the patients reported at least one adverse event. Pain at the injection site, fatigue, headache, arthralgia, and myalgia were the most common symptoms. The prevalence of adverse events decreased over time (65.8% on day 0, 27.4% between days 0 and 21, and 24.6% between days 21 and 180). Severe acute respiratory syndrome coronavirus 2 infection after the 1st dose occurred in 17 patients (23.3%) and one of the patients (5.88%) was hospitalized due to infection. Conclusions Adverse events after COVID-19 vaccination were generally mild in children and adolescents with underlying medical conditions. Our findings provide evidence for the safety of COVID-19 vaccination in the vulnerable pediatric population. |
| first_indexed | 2024-03-12T02:32:42Z |
| format | Article |
| id | doaj.art-3fb8784971c548b893d9ef7b08c0a1b7 |
| institution | Directory Open Access Journal |
| issn | 2384-0242 2384-0250 |
| language | English |
| last_indexed | 2024-03-12T02:32:42Z |
| publishDate | 2023-06-01 |
| publisher | Korean Society of Pediatric Nephrology |
| record_format | Article |
| series | Childhood Kidney Diseases |
| spelling | doaj.art-3fb8784971c548b893d9ef7b08c0a1b72023-09-05T04:20:02ZengKorean Society of Pediatric NephrologyChildhood Kidney Diseases2384-02422384-02502023-06-01271343910.3339/ckd.23.004781Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort studyNaye Choi0Seung-Ah Choe1Yo Han Ahn2Young June Choe3Ju-Young Shin4Nam-Kyong Choi5Seong Heon Kim6Hee Gyung Kang7 Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Republic of Korea Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Republic of Korea Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, Republic of Korea Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Republic of Korea Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Republic of KoreaPurpose This article was to collect data on the safety of coronavirus disease 2019 (COVID-19) vaccines in children with underlying medical conditions. Methods We constructed a prospective cohort of children and adolescents aged 5 to 19 years who had received at least one dose of COVID-19 vaccine. Patients diagnosed with and treated for chronic kidney disease, autoimmune disease, or other chronic conditions at the Seoul National University Children’s Hospital were recruited from June to December 2022. A mobile survey questionnaire was sent to their guardians. The presence of adverse events on the day (day 0), 3 weeks (day 21), and 6 months (day 180) after the 1st dose of COVID-19 vaccine was recorded by the guardians. Results A total of 73 children participated. The median age was 14 years, and 64.4% of the patients were male. On the day of immunization, 65.8% of the patients reported at least one adverse event. Pain at the injection site, fatigue, headache, arthralgia, and myalgia were the most common symptoms. The prevalence of adverse events decreased over time (65.8% on day 0, 27.4% between days 0 and 21, and 24.6% between days 21 and 180). Severe acute respiratory syndrome coronavirus 2 infection after the 1st dose occurred in 17 patients (23.3%) and one of the patients (5.88%) was hospitalized due to infection. Conclusions Adverse events after COVID-19 vaccination were generally mild in children and adolescents with underlying medical conditions. Our findings provide evidence for the safety of COVID-19 vaccination in the vulnerable pediatric population.http://chikd.org/upload/pdf/ckd-23-004.pdfadolescentchildcovid-19safetysars-cov-2 |
| spellingShingle | Naye Choi Seung-Ah Choe Yo Han Ahn Young June Choe Ju-Young Shin Nam-Kyong Choi Seong Heon Kim Hee Gyung Kang Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study Childhood Kidney Diseases adolescent child covid-19 safety sars-cov-2 |
| title | Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study |
| title_full | Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study |
| title_fullStr | Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study |
| title_full_unstemmed | Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study |
| title_short | Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study |
| title_sort | short term safety profile of covid 19 vaccination in children and adolescents with underlying medical conditions a prospective cohort study |
| topic | adolescent child covid-19 safety sars-cov-2 |
| url | http://chikd.org/upload/pdf/ckd-23-004.pdf |
| work_keys_str_mv | AT nayechoi shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy AT seungahchoe shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy AT yohanahn shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy AT youngjunechoe shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy AT juyoungshin shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy AT namkyongchoi shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy AT seongheonkim shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy AT heegyungkang shorttermsafetyprofileofcovid19vaccinationinchildrenandadolescentswithunderlyingmedicalconditionsaprospectivecohortstudy |